Funding Opportunities

This is a curated list of funding opportunities for Cancer Center members.

Intramural Funding Opportunities

ACS-Institutional Research Grant (IRG) 2023 Diversity, Equity and Inclusion Pilot Project Program

Sponsor: American Cancer Society

Abstract: The ACS IRGs are awarded to institutions as block grants and provide seed money for newly independent investigators to initiate cancer research projects. The intent is to support junior faculty in initiating cancer research projects so they can obtain preliminary results that will enable them to compete successfully for national research grants. This grant is limited to those from populations that are underrepresented in science.

Application Due Date: February 20, 2023

Extramural Funding Opportunities

The Bosarge Family Foundation – Waun Ki Hong Scholar Award for Regenerative Cancer Medicine

Sponsor: American Association for Cancer Research

Abstract: Postdoctoral and clinical fellows are invited to apply for this two-year, $120,000 grant to support salary and benefits, while working on a mentored regenerative cancer medicine project. The proposed research must be translational, clinical, or epidemiological in nature and must have applicability and relevance to enhancing the physiology of cancer survivors using regenerative medicine.

Application Due Date: February 7, 2023

Pediatric Cancer Research Grant

Sponsor: Pediatric Cancer Research Foundation

Abstract: At PCRF, we are unique in our approach to funding childhood cancer research — working directly with doctors, researchers, and nurses to identify the specific challenges they face in bringing new treatments to and caring for children with cancer. Our careful distribution of grants has allowed doctors and nurses to speed up the process of bringing the latest and most promising life-saving treatments to seriously ill children. The result is bringing hope to childhood cancer patients now and in the future.

The Pediatric Cancer Research Foundation awards four types of grants:

– Emerging Investigator

– Translational Research Grants

– Basic Science Grants * Not offered in the 2023 cycle. *

– Designated Grant Programs

Internal LOI Due Date: February 8, 2023

Sponsor LOI Due Date: March 1, 2023

Application Due Date: June 1, 2023

Breast Cancer Research Foundation – AACR Career Development Awards to Promote Diversity and Inclusion

Sponsor: American Association for Cancer Research

Abstract: We invite early-career investigators to submit applications for the Breast Cancer Research Foundation-AACR Career Development Awards to Promote Diversity and Inclusion. These two-year, $150,000 grants support ethnic and racial minority researchers underrepresented in the biomedical workforce who are focused on innovative breast cancer treatment approaches and/or novel insights on disparities in breast cancer.

Application Due Date: February 13, 2023

Call for Independent Medical Education Grant Applications, Oncology – Prostate Cancer

Sponsor: Astellas; Pfizer

Abstract: The purpose of this CGA is to encourage Organizations to submit medical education grant applications for independent CME/CE certified education designed to close an independently identified education gap, drive measurable improvements in competence and performance of healthcare professionals, and enhance understanding of the management for HSPC for both HCP and patient/caregiver audiences. Grant proposals should leverage innovative data delivery mechanisms including an omnichannel approach.

Application Due Date: February 24, 2023

Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

Sponsor: National Institutes of Health (NIH); National Cancer Institute (NCI)

Abstract: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns this can include a pilot/feasibility clinical trial if necessary, improving trial design and rigor.

Application Due Date: February 24, 2023; June 26, 2023

Aging & Cancer Research with the Mark Foundation

Sponsor: Samuel Waxman Cancer Research Foundation; The Mark Foundation for Cancer Research

Abstract: The Samuel Waxman Cancer Research Foundation (SWCRF) and The Mark Foundation for Cancer Research are pleased to issue a joint Request for Applications (RFA) for collaborative projects to focus on Aging and Cancer. Projects must include collaborations between two laboratories with different but complementary expertise. Proposals must justify the partnership through synergistic scientific aims. Awards will provide $500,000 total over three years ($250,000 to each PI).

LOI due date: March 1, 2023

Application Due Date: June 1, 2023

2023 Prostate Cancer Foundation (PCF) Challenge Awards for metastatic, Lethal Prostate Cancer

Sponsor: Prostate Cancer Foundation (PCF)

Abstract: PCF is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. We especially encourage applications on prostate cancer disparity research that will help to define the origins of differential outcome for prostate cancer patients in men of under-represented populations, including those focusing on biology or health care access policy. We also seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer.

LOI Due Date: March 10, 2023

Application Due Date: May 15, 2023

AHEAD (Advancing Health Equity and Addressing Cancer Disparities) Awards

Sponsor: American Cancer Society

Abstract:  The Awards intended to fund pilot, first-in-field, innovative strategies that increase quality cancer screening, clinical trials—and cancer care closer to home.

AHEAD Awards will fund exploratory, novel research studies that seek to improve access to quality cancer screening and/or cancer care by bringing technologies to individuals rather than requiring travel to health care facilities. A scientist’s proposed research may break new ground or strategize a new application of existing technologies or new intervention. We encourage the testing of high-risk, high-reward pilot projects to maximize the likelihood for breakthrough research and clinical impact.

Application Due Date: April 2, 2023

Notices of Special Interests

Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways

Sponsor: National Cancer Institute NCI)

Abstract: The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences’ interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and testing approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways.

Risk-stratified survivorship care describes a personalized approach to care in which cancer survivors are triaged or stratified to distinct care pathways based on the complexity of their needs and the types of providers their care requires.

Application Due Date: February 4, 2023

Translate »